Research map: ctDNA Detection of Polyclonal KRAS Resistance in Adagrasib‐Treated NSCLC

Back to the article

Papers in this map

  1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation · Ferdinandos Skoulidis · 2021 · 1874 citations · Cited by this paper
  2. Histone Variant H2A . Z2 Hyper‐Transcription Induced by E2F1 Accelerates Lung Adenocarcinoma Progression via the JAK – STAT Signaling Pathway · 2026 · Related
  3. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma · Ferdinandos Skoulidis · 2018 · 1675 citations · Cited by this paper
  4. Synchronous Surgical Therapy for Bilateral Multiple Pulmonary Nodules: A Single‐Center Analysis of 108 Cases · 2026 · Related
  5. Acquired Resistance to KRAS G12C Inhibition in Cancer · Mark M. Awad · 2021 · 1244 citations · Cited by this paper
  6. Importance of Multimodal Testing for Novel ALK Fusions: A Case of MTHFD1L‐ALK Positive Lung Squamous Cell Carcinoma With Negative IHC · 2026 · Related
  7. Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation · Pasi Antero Janne · 2022 · 1052 citations · Cited by this paper
  8. Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management · 2026 · Related
  9. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group · Javier Pascual · 2022 · 738 citations · Cited by this paper
  10. Incidence Patterns and Prognostic Impact of Lung‐Involving Multiple Primary Cancers: A 10‐Year Hospital‐Based Cohort Study · 2026 · Related
  11. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients · Jacob J. Chabon · 2016 · 670 citations · Cited by this paper
  12. Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study · 2026 · Related
  13. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation · Noritaka Tanaka · 2021 · 536 citations · Cited by this paper
  14. First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK ‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam · 2026 · Related
  15. Diverse alterations associated with resistance to KRAS(G12C) inhibition · Yulei Zhao · 2021 · 474 citations · Cited by this paper
  16. Advanced Thymoma and Advanced Thymic Carcinoma Treatment Practices in 2018–2022: A Nationwide Analysis in Japan · 2026 · Related
  17. Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA · Ibiayi Dagogo‐Jack · 2018 · 133 citations · Cited by this paper
  18. Multi‐Omics Analysis Reveals Differentially Expressed Proteins and Metabolites in Malignant Pleural Effusion · 2026 · Related
  19. Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non–small Cell Lung Cancer · Malene S. Frank · 2022 · 22 citations · Cited by this paper
  20. Case Report: Rare Peripheral Neuropathy With Abdominal Wall Allodynia in Extensive‐Stage Small‐Cell Lung Cancer Treated Using Durvalumab · 2026 · Related
  21. MobiCT: a UMI-based circulating tumor DNA analysis pipeline · Simon Cabello‐Aguilar · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)